ES2375614T3 - Derivados de espiro tric�?clicos como moduladores de crth2 - Google Patents

Derivados de espiro tric�?clicos como moduladores de crth2 Download PDF

Info

Publication number
ES2375614T3
ES2375614T3 ES06763238T ES06763238T ES2375614T3 ES 2375614 T3 ES2375614 T3 ES 2375614T3 ES 06763238 T ES06763238 T ES 06763238T ES 06763238 T ES06763238 T ES 06763238T ES 2375614 T3 ES2375614 T3 ES 2375614T3
Authority
ES
Spain
Prior art keywords
chloro
indole
pyrrolidin
acetic acid
trioxospiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06763238T
Other languages
English (en)
Spanish (es)
Inventor
Matthias Schwarz
Eric Sebille
Christophe Cleva
Cedric Merlot
Dennis Church
Patrick Page
Jacqueline A. Macritchie
John Frederick Atherall
Stefano Crosignani
Doris Pupowicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono SA filed Critical Merck Serono SA
Application granted granted Critical
Publication of ES2375614T3 publication Critical patent/ES2375614T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES06763238T 2005-05-24 2006-05-23 Derivados de espiro tric�?clicos como moduladores de crth2 Active ES2375614T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05104428 2005-05-24
EP05104428 2005-05-24
US68863105P 2005-06-08 2005-06-08
US688631P 2005-06-08
PCT/EP2006/062545 WO2006125784A1 (en) 2005-05-24 2006-05-23 Tricyclic spiro derivatives as crth2 modulators

Publications (1)

Publication Number Publication Date
ES2375614T3 true ES2375614T3 (es) 2012-03-02

Family

ID=35478408

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06763238T Active ES2375614T3 (es) 2005-05-24 2006-05-23 Derivados de espiro tric�?clicos como moduladores de crth2

Country Status (20)

Country Link
US (1) US8236963B2 (https=)
EP (1) EP1891075B1 (https=)
JP (1) JP5567268B2 (https=)
KR (1) KR101333861B1 (https=)
CN (1) CN101300259B (https=)
AR (1) AR055959A1 (https=)
AT (1) ATE529429T1 (https=)
AU (1) AU2006251138C1 (https=)
BR (1) BRPI0610209A2 (https=)
CA (1) CA2602965C (https=)
DK (1) DK1891075T3 (https=)
ES (1) ES2375614T3 (https=)
MX (1) MX2007014256A (https=)
NZ (1) NZ562772A (https=)
PL (1) PL1891075T3 (https=)
PT (1) PT1891075E (https=)
RU (1) RU2478639C2 (https=)
UA (1) UA90145C2 (https=)
WO (1) WO2006125784A1 (https=)
ZA (1) ZA200709819B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0715179A2 (pt) 2006-08-07 2013-06-11 Actelion Pharmaceuticals Ltd composto, composiÇço farmacÊutica e uso de um composto
US20120115895A1 (en) 2009-07-15 2012-05-10 Merck Serono S.A. Tricyclic indole-derived spiro derivatives as crth2 modulators
KR20120099462A (ko) 2009-11-12 2012-09-10 더 리젠츠 오브 더 유니버시티 오브 미시건 스피로-옥신돌 mdm2 길항제
PT2558447E (pt) 2010-03-22 2014-11-25 Actelion Pharmaceuticals Ltd Derivados de 3-(heteroarilamino)-1,2,3,4-tetrahidro-9hcarbazol e o seu uso como moduladores do receptor de prostaglandina d2
AU2011326395B2 (en) 2010-11-12 2016-01-07 Ascenta Licensing Corporation Spiro-oxindole MDM2 antagonists
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
DK2697223T3 (en) 2011-04-14 2016-09-05 Actelion Pharmaceuticals Ltd 7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor
US8629141B2 (en) 2011-05-11 2014-01-14 The Regents Of The University Of Michigan Spiro-oxindole MDM2 antagonists
EP2790696A1 (en) 2011-12-16 2014-10-22 Atopix Therapeutics Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
CN103554118B (zh) * 2013-10-15 2015-08-19 华东师范大学 四氢呋喃并苯并二氢吡喃多环化合物及其应用
CN103554119B (zh) * 2013-10-15 2015-09-16 华东师范大学 四氢呋喃并苯并二氢吡喃多环化合物的制备方法
CN103554120B (zh) * 2013-10-16 2015-06-24 华东师范大学 3,3-螺(2-四氢呋喃)氧化吲哚多环状化合物的制备方法
CN103554121B (zh) * 2013-10-16 2015-06-24 华东师范大学 3,3-螺(2-四氢呋喃)氧化吲哚多环状化合物及其应用
AR099767A1 (es) 2014-03-17 2016-08-17 Actelion Pharmaceuticals Ltd Derivados del ácido acético azaindol y su uso como moduladores del receptor de prostaglandina d2
KR20160133536A (ko) 2014-03-18 2016-11-22 액테리온 파마슈티칼 리미티드 아자인돌 아세트산 유도체 및 프로스타글란딘 d2 수용체 조절제로서의 이의 용도
US9745253B2 (en) 2015-03-13 2017-08-29 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
ES2733468T3 (es) 2015-07-15 2019-11-29 Hoffmann La Roche Derivados de etinilo como moduladores de los receptores metabotrópicos de glutamato
AU2016323262B2 (en) 2015-09-15 2020-11-19 Idorsia Pharmaceuticals Ltd Crystalline forms
RU2631856C1 (ru) * 2016-05-04 2017-09-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова" Способ получения аммонийных солей 3-амино-8-гидрокси-1,6-диоксо-4-циано-2,7-диазаспиро[4.4]нон-3-ен-2-идов
WO2018015235A1 (en) 2016-07-18 2018-01-25 F. Hoffmann-La Roche Ag Ethynyl derivatives
CN109384787B (zh) * 2017-08-08 2021-04-16 沈阳药科大学 一种一价银催化的氢化吡啶螺二氢吲哚环的合成方法
CN109384794B (zh) * 2017-08-08 2020-06-19 沈阳药科大学 质子酸催化的一类四环吲哚骨架的合成方法
CN109369658B (zh) * 2017-08-08 2020-01-31 沈阳药科大学 一种螺[吡咯烷-3,3`-氧化吲哚]环系的合成方法
KR101857408B1 (ko) 2018-02-28 2018-05-14 경북대학교 산학협력단 탈모 예방 또는 치료용 조성물
EP3902805A4 (en) 2018-12-28 2023-03-01 SPV Therapeutics Inc. CYCLINE-DEPENDENT KINASE INHIBITORS
CN112876488B (zh) * 2021-02-18 2021-12-21 苏州大学 螺环吲哚啉衍生物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52879B1 (en) * 1981-05-12 1988-03-30 Ici Plc Pharmaceutical spiro-hydantoin derivatives
IE53102B1 (en) 1981-05-12 1988-06-22 Ici Plc Pharmaceutical spiro-succinimide derivatives
US5948807A (en) * 1997-09-03 1999-09-07 Regents Of The University Of Minnesota Spiroindanamines and Spiroindanimides
NZ528846A (en) * 1999-03-12 2005-05-27 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
SE0200411D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
GB2388540A (en) 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban
AU2003277285B2 (en) 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
EP1556356B1 (en) 2002-10-21 2006-05-31 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as crth2 antagonists
DE60303238T2 (de) 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
US20050038070A1 (en) 2003-07-09 2005-02-17 Amgen Inc. Asthma and allergic inflammation modulators
MXPA06011891A (es) 2004-04-20 2007-04-24 Pfizer Metodo para tratar el dolor neuropatico.

Also Published As

Publication number Publication date
EP1891075A1 (en) 2008-02-27
JP2008542238A (ja) 2008-11-27
JP5567268B2 (ja) 2014-08-06
RU2007147430A (ru) 2009-06-27
CN101300259B (zh) 2013-08-28
AU2006251138A1 (en) 2006-11-30
ATE529429T1 (de) 2011-11-15
AU2006251138C1 (en) 2013-08-29
NZ562772A (en) 2010-01-29
UA90145C2 (ru) 2010-04-12
AR055959A1 (es) 2007-09-12
RU2478639C2 (ru) 2013-04-10
CA2602965C (en) 2013-12-31
US8236963B2 (en) 2012-08-07
BRPI0610209A2 (pt) 2010-06-01
US20090318486A1 (en) 2009-12-24
PL1891075T3 (pl) 2011-12-30
KR101333861B1 (ko) 2013-11-28
PT1891075E (pt) 2011-11-10
ZA200709819B (en) 2009-09-30
MX2007014256A (es) 2008-03-26
DK1891075T3 (da) 2011-12-19
CN101300259A (zh) 2008-11-05
CA2602965A1 (en) 2006-11-30
EP1891075B1 (en) 2011-10-19
KR20080031191A (ko) 2008-04-08
AU2006251138B2 (en) 2012-08-09
WO2006125784A1 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
ES2375614T3 (es) Derivados de espiro tric�?clicos como moduladores de crth2
RU2571100C2 (ru) Спироиндолинонпирролидины, полезные при лечении злокачественных новообразований
US8431565B2 (en) Substituted imidazoheterocycles
CN105517999B (zh) Ido抑制剂
ES2403284T3 (es) Pirimidil ciclopentanos como inhibidores de la proteína quinasa AKT
CN105473550A (zh) Ido抑制剂
ES2745284T3 (es) Heteroarilos sustituidos con pirazolilo y su uso como medicamentos
RS56076B1 (sr) Inhibitori piridiloksiindola za vegf-r2 i njihova upotreba za tretman oboljenja
KR20160055190A (ko) 트립토판 하이드록실레이스 억제제로서 스파이로사이클릭 화합물
TW201107335A (en) Compounds-801
US8835422B2 (en) Substituted imidazoheterocycle derivatives
CN118139862A (zh) 含氮杂环类化合物及其医药用途
TW201607941A (zh) T型鈣通道阻礙劑
JP2023546226A (ja) 統合ストレス応答経路のモジュレーター
TWI357897B (en) 3-substituted-5- and 6-aminoalkyl indole-2-carboxy
HK1121146A1 (en) Tricyclic spiro derivatives as crth2 modulators
HK1121146B (en) Tricyclic spiro derivatives as crth2 modulators
WO2024240086A1 (zh) 一种调控15-pgdh活性的化合物及其制备方法
JP2026503850A (ja) Trpa1阻害剤としての二環式イミド化合物